VEGFA and cancer: Following a single administration of MRX34, multiple oncogenes of the key cancer pathways were inhibited, including WnT/b-Catenin, MapK, c-Met, Hedgehog, and vascular endothelial growth factor (VEGF), while multiple genes of the p53 pathway were stimulated [124].